TReatment Approaches and bIomarkers preValence in bladdEr Cancer in RuSsian Federation

Inclusion Criteria12

• Age ≥ 18 years;
• Signed ICF, including consent for FFPE tumor tissue sample testing;
• Confirmed diagnosis of urothelial bladder cancer at NMIBC, MIBC, or mBC stage at study entry;
• For patients with NMIBC: 1. TURBT performed at least 1 month but not more than 12 months prior to study entry; 2. Presence of ≥1 high-risk feature:
• T1 tumor
• High grade/G3 tumor
• CIS (carcinoma in situ)
• Multiple and recurrent and large (with diameter of largest tumor ≥3 cm) tumors (all conditions must be met in this point);
• For patients with MIBC: Сystectomy performed at least 2 months but not more than 12 months prior to study entry;
• For patients with mBC: mBC diagnosed during 12 months prior to study entry;
• Availability of medical history data;
• Availability of FFPE tumour tissue sample obtained during biopsy and/or surgery.